Fig. 1From: Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironmentElucidation of the mechanism of action of TKIs. Sorafenib, lenvatinib, regorafenib, and lenvatinib exert the antitumour activity through blockage of specific targets, subsequently inhibiting of subsequent signalling pathways and eventually inhibiting the proliferation, angiogenesis, migration and survival of tumour cellsBack to article page